Unicycive Therapeutics, Inc.
NASDAQ:UNCYBiotechnology
-$0.24 today
- Market cap
- $104.19M
- Beta
- 1.73
- P/E (TTM)
- -40.8
- EPS (TTM)
- -$0.17
Volume 1.39M
Average 0.65M
UNCY Total Assets
Everything the company owns or controls; equal to total liabilities plus equity.
Unicycive Therapeutics, Inc.NASDAQ: UNCY
Total Assets · Q1 FY2026 · quarter ended Mar 2026
Total assets rises 130.5% from a year ago
Total assets stood at $64.41M at the end of Q1 FY2026, up 130.5% from a year earlier and up 31.1% from the prior quarter. Over 3 fiscal years it compounded at +159.3% a year.
Context
- Total assets increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total assets keeps rising in the next quarterly balance sheet after a +130.5% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Assets history
USD · from the balance sheet
- Latest · FY2025
- 49.14M USD
- Year-over-year change
- +55.2%
- 4-year CAGR
- +27.2%
| Period | Period end | Total Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 49.14M | +55.2% |
| FY2024 | 2024-12-31 | 31.67M | +123.2% |
| FY2023 | 2023-12-31 | 14.19M | +403.6% |
| FY2022 | 2022-12-31 | 2.82M | -85.0% |
| FY2021 | 2021-12-31 | 18.74M | — |
Total Assets vs competitors
How UNCY compares with its peers on the latest reported figures
- Peers report in different currencies, so total assets is compared through growth and rates rather than absolute size.
- Its year-over-year change of +130.5% is the 3rd highest of 10, against a peer median of -3.2%.
- Over three fiscal years its annual growth of +159.3% compares with a peer median of -18.5%.
| Company | Period | Latest balance | YoY | 3-year CAGR |
|---|---|---|---|---|
CBUSCibus, Inc. | Mar 2026 | $324.2M USD | -3.2% | +138.7% |
| Mar 2026 | $235.36M USD | +750.3% | -15.0% | |
| Mar 2026 | $189.74M USD | +824.9% | -42.7% | |
| Mar 2026 | $180.06M USD | +13.6% | +6.5% | |
ACRVAcrivon Therapeutics, Inc. Common Stock | Mar 2026 | $107.83M USD | -38.9% | -10.5% |
| Mar 2026 | $105.46M USD | +68.0% | — | |
| Mar 2026 | $96.56M USD | -43.4% | -24.5% | |
| Mar 2026 | $64.41M USD | +130.5% | +159.3% | |
| Mar 2026 | $46.39M USD | -15.7% | -23.2% | |
HYFTMindWalk Holdings Corp. | Jan 2026 | CA$23.17M CAD | -49.1% | -22.0% |
| Peer median (excluding UNCY) | — | -3.2% | -18.5% | |
Competitors are the stored peer set for UNCY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Unicycive Therapeutics, Inc.
NASDAQ:UNCY
Intrinsic Alpha fair value
Locked
Current Price
$3.57
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.